Confronto
Degarelix vs. Pasireotid
Due peptidi a confronto — identità, base di evidenze, stato legale ed eventi avversi noti.
Identità
Categoria
Ricerca (altro)
Ricerca (altro)
N. CAS
214766-78-6
396091-73-9
Peso molecolare
1632.3 g/mol
1047.21 g/mol
Emivita
1320 h
nessun dato
Sequenza
Ac-D-2Nal-D-4Cpa-D-3Pal-Ser-4Aph(Hor)-D-4Aph(Cbm)-Leu-Ilys-Pro-D-Ala-NH2nessun dato
Meccanismo d'azione
Degarelix
Degarelix is a competitive GnRH receptor antagonist. It binds reversibly and immediately to the pituitary GnRH receptors and blocks their activation. This rapidly suppresses the release of luteinizing hormone (LH) and follicle-stimulating hormone (FSH), which in turn lowers testosterone production in the testes. Unlike GnRH agonists (e.g., leuprorelin), which first cause a transient stimulation with a testosterone surge (flare), this direct antagonism lacks the initial stimulation phase, so testosterone declines without a preceding rise. This mechanism underlies the literature-described use in hormone-dependent prostate cancer.
Pasireotid
Pasireotide binds more broadly than older somatostatin analogs (SSTR1/2/3/5) with particularly high affinity for SSTR5. This suppresses, among others, ACTH release in Cushing's disease and GH release in acromegaly.
Base di evidenze
Evidenza più alta
RCT sull'uomo
RCT sull'uomo
Studi
4
1
di cui sull'uomo
4
1
Effetti registrati
4
2
Contraddizioni aperte
1
0
Eventi avversi documentati
2
2
Stato legale
Voci complete
Frequently asked questions
- What is the difference between Degarelix and Pasireotid?
- Degarelix is classified as "Ricerca (altro)", while Pasireotid is classified as "Ricerca (altro)". Degarelix: Degarelix (trade name Firmagon) is a synthetic decapeptide and a gonadotropin-releasing hormone (GnRH) receptor antagonist. Unlike GnRH agonists, it blocks the receptor directly and does not trigger an initial testosterone surge (flare). It is an approved prescription medicine for the treatment of advanced, hormone-dependent prostate cancer. This page neutrally summarizes the evidence base and legal status and is not a usage or dosing recommendation. Pasireotid: Pasireotide is a multireceptor somatostatin analog binding to four of the five somatostatin receptors (especially SSTR5). It is approved for Cushing's disease and acromegaly. This page contrasts both neutrally and source-based — with no usage or dosing recommendation.
- Which peptide is better supported by science, Degarelix or Pasireotid?
- The highest available evidence level is "RCT sull'uomo" for Degarelix and "RCT sull'uomo" for Pasireotid. A higher evidence level means more robust data, but says nothing about suitability for an individual. The full body of evidence is on each peptide's own page.
- What is the legal status of Degarelix and Pasireotid in Germany and the United States?
- Germania: Degarelix — Su prescrizione, Pasireotid — Su prescrizione. Stati Uniti: Degarelix — Su prescrizione, Pasireotid — Su prescrizione. These are factual summaries with source and review date on the individual pages.